CBD Stock Overview
Engages in the retail and wholesale of products based on hemp containing cannabidiol (CBD) in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cannabis Poland S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.46 |
| 52 Week High | zł1.04 |
| 52 Week Low | zł0.30 |
| Beta | 0.69 |
| 11 Month Change | -8.47% |
| 3 Month Change | -6.03% |
| 1 Year Change | 21.88% |
| 33 Year Change | -76.86% |
| 5 Year Change | -32.03% |
| Change since IPO | -58.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| CBD | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | -3.5% | 3.9% | -0.2% |
| 1Y | 21.9% | 49.6% | 0.3% |
Return vs Industry: CBD underperformed the Polish Pharmaceuticals industry which returned 49.6% over the past year.
Return vs Market: CBD exceeded the Polish Market which returned 0.3% over the past year.
Price Volatility
| CBD volatility | |
|---|---|
| CBD Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.4% |
| 10% least volatile stocks in PL Market | 2.9% |
Stable Share Price: CBD's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: CBD's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1 | n/a | www.cp-sa.pl |
Cannabis Poland S.A. engages in the retail and wholesale of products based on hemp containing cannabidiol (CBD) in Poland. The company sells CBD oils and herbs, inhalers, and vaporizers, as well as cosmetics. It sells its products through HempWish.pl and Vapem.eu online stores.
Cannabis Poland S.A. Fundamentals Summary
| CBD fundamental statistics | |
|---|---|
| Market cap | zł22.61m |
| Earnings (TTM) | -zł1.47m |
| Revenue (TTM) | zł265.26k |
85.2x
P/S Ratio-15.4x
P/E RatioIs CBD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBD income statement (TTM) | |
|---|---|
| Revenue | zł265.26k |
| Cost of Revenue | zł291.28k |
| Gross Profit | -zł26.01k |
| Other Expenses | zł1.44m |
| Earnings | -zł1.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | -9.81% |
| Net Profit Margin | -553.06% |
| Debt/Equity Ratio | 4.4% |
How did CBD perform over the long term?
See historical performance and comparison